Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsIntellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)October 19, 2020Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid CardiomyopathyResults From ATTRibute-CM and Its Open-Label ExtensionNovember 12, 20252025 Spring NewsletterMay 21, 2025 Previous post2026 Winter Newsletter